Lower-Dose Venetoclax Shows Promise for Chinese Patients with Hematological Malignancies
核心洞察
A real-world study of 76 Chinese patients demonstrates that lower-dose venetoclax regimens (200 mg daily) can achieve clinical outcomes comparable to standard 400 mg doses, potentially improving treatment accessibility and affordability.
Chinese patients showed significantly different pharmacokinetic profiles compared to non-Asian populations, with 30% lower drug clearance rates requiring population-specific dosing strategies.
The research identified a clear exposure-response relationship, with overall response rates improving from 42% at 100 mg to 68% at 200 mg daily, suggesting minimal benefit from higher doses.
A prospective real-world study conducted at Southwest Hospital (搜索) in Chongqing has revealed that Chinese patients with hematological malignancies (搜索) may achieve effective treatment outcomes with lower doses of venetoclax than currently recommended, potentially addressing cost and accessibility barriers while maintaining therapeutic efficacy.
The research, published in Drug Design, Development and Therapy, analyzed 121 venetoclax concentration samples from 76 Chinese patients diagnosed with various blood cancers, including 63 cases of acute myeloid leukemia (搜索) (AML), 7 cases of myelodysplastic syndrome (搜索), and other hematological malignancies (搜索). All patients received combination chemotherapy with agents including azacitidine, aclarubicin, cytarabine, and other standard treatments.
Significant Pharmacokinetic Differences in Chinese Population
The study identified substantial differences in venetoclax pharmacokinetics between Chinese and non-Asian populations. External evaluation of six previously published population pharmacokinetic models revealed systematic underprediction of drug concentrations in Chinese patients, with all models showing significant prediction biases far beyond the acceptable ±30% range.
To address these discrepancies, researchers developed a Chinese-specific population pharmacokinetic model. The analysis revealed a markedly lower apparent clearance rate of 7.33 L/h in Chinese patients compared to 15-19.54 L/h reported in previous studies conducted primarily in non-Asian populations. This finding aligns with earlier observations showing approximately 67% higher venetoclax bioavailability in Asian patients compared to non-Asians.
"The Asian populations exhibited approximately 30% lower clearance compared to other regions," the researchers noted, emphasizing the need for population-specific dosing strategies rather than applying protocols developed for other ethnic groups.
Dose-Response Analysis Supports Lower Dosing
The study demonstrated a clear exposure-response relationship for venetoclax in Chinese patients with AML. Overall response rates improved significantly from 42% at 100 mg daily to 68% at 200 mg daily. However, only limited improvement was observed when doses increased from 200 mg to 400 mg, suggesting minimal clinical benefit from higher doses.
Therapeutic drug monitoring data provided additional support for lower dosing strategies. The average venetoclax minimum concentration in patients receiving 200 mg daily was 1,470.18 ± 855.63 ng/mL, closely aligning with concentrations previously reported in patients receiving 400 mg doses in other populations, including Chinese (1,018 ± 729 ng/mL), Japanese (1,020 ng/mL), and French populations (1,010 ± 470 ng/mL).
These concentrations significantly exceeded those reported from registered clinical trials (490-840 ng/mL) and approximated the optimal therapeutic target concentration of 1,200 ng/mL, suggesting that 200 mg daily could represent the minimum effective dosage for Chinese patients.
Clinical Implications for Treatment Accessibility
The findings have important implications for treatment accessibility and cost management in China. Venetoclax, a first-in-class oral BCL-2 (搜索) inhibitor, has revolutionized treatment for chronic lymphocytic leukemia (搜索) and AML but remains expensive. The research suggests that lower doses could maintain therapeutic efficacy while reducing financial burden on patients and healthcare systems.
"Approximately 40% of our patients receiving lower daily doses (100-200 mg) achieved relatively high trough concentrations, further supporting the feasibility of dose individualization based on real-world therapeutic drug monitoring data," the authors reported.
The study also highlighted the importance of real-world evidence in guiding clinical practice. Unlike controlled clinical trials, real-world factors such as variable dietary intake and less standardized medication timing likely increase interindividual pharmacokinetic variability, making population-specific dosing strategies even more critical.
Study Methodology and Limitations
The prospective, non-interventional study was conducted from July 2021 to March 2024, with patients aged 36 to 63 years. Efficacy outcomes were assessed through bone marrow biopsies performed after completion of one treatment cycle, typically between day 28 and day 45 after venetoclax initiation.
Venetoclax concentrations were measured using a validated liquid chromatography-tandem mass spectrometry method, with venous blood drawn before the next dose administration. The lower limit of quantitation was 20 ng/mL, with intra-day and inter-day precision values of ≤8.05% and ≤9.49%, respectively.
The researchers acknowledged several limitations, including the single-center design with a relatively small sample size and sampling solely from trough concentrations, which may not fully reflect the drug's absorption and distribution characteristics. They called for multi-center, prospective studies with larger patient cohorts and comprehensive sampling schedules to confirm and extend these findings.
Future Directions for Personalized Dosing
The research supports the growing emphasis on therapeutic drug monitoring and pharmacokinetically guided dosing strategies to minimize variability and improve efficacy. The authors suggested that when average venetoclax plasma concentrations exceed 1,777 ng/mL, remission rates no longer increase significantly, indicating minimal clinical benefit from higher doses.
These findings reinforce the hypothesis that the optimal therapeutic exposure range may be between 1,000 and 2,000 ng/mL, highlighting both clinical and economic advantages of therapeutic drug monitoring for individualized dosing in Chinese patients with hematological malignancies (搜索).
The study provides important real-world evidence for dose optimization in oncology, demonstrating how population-specific pharmacokinetic differences can inform more effective and accessible treatment strategies. As precision medicine continues to evolve, such research may guide the development of individualized dosing protocols that maximize therapeutic benefit while minimizing toxicity and cost.